	US 12,292,451 B2
	ApoA1 exchange rate assays in serum
Jonathan D. Smith, Shaker Heights, OH (US); Stanley L. Hazen, Pepper Pike, OH (US); and Shuhui Wang Lorkowski, Shaker Heights, OH (US)
Assigned to CLEVELAND CLINIC FOUNDATION, Cleveland, OH (US)
Appl. No. 15/734,631
Filed by The Cleveland Clinic Foundation, Cleveland, OH (US)
PCT Filed Jun. 3, 2019, PCT No. PCT/US2019/035228 § 371(c)(1), (2) Date Dec. 3, 2020, PCT Pub. No. WO2019/236486, PCT Pub. Date Dec. 12, 2019.
Claims priority of provisional application 62/682,628, filed on Dec. 3, 2020.
Prior Publication US 2021/0231691 A1, Jul. 29, 2021
Int. Cl. G01N 33/92 (2006.01); G16H 15/00 (2018.01); G16H 50/30 (2018.01)

CPC G01N 33/92 (2013.01) [G16H 15/00 (2018.01); G16H 50/30 (2018.01); G01N 2333/775 (2013.01)]

9 Claims

1. A method of detecting lipid-free apoA1 reporter molecules in a serum sample from a human subject comprising:

a) contacting a serum sample from a human subject with lipid-free apoA1 reporter molecules,

wherein said serum sample comprises HDL molecules and LDL molecules,

wherein said lipid-free apoA1 reporter molecules each comprise at least a portion of human ApoA1 that is labeled with: i) nitrobenzoxadiazole, a lipid sensitive label whose fluorescence increases in a hydrophobic environment, and ii) a lipid insensitive fluorescent label; and

b) detecting: i) a first signal from said lipid sensitive label, and ii) a second signal from said lipid insensitive label, wherein said lipid-free apoA1 reporter molecules exchange into said HDL molecules in said serum sample at a rate detectable by said first and second signals together.